Ponatinib in treatment of chronic myeloid leukemia with T315I mutation.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 33, doi. 10.5603/HCP.2021.0006
- By:
- Publication type:
- Article
Works matching IS 27201015 AND DT 2021 AND VI 31 AND IP 1
Results: 6
1
2
Secondary immune thrombocytopenia after Streptococcus infection.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 29, doi. 10.5603/HCP.2021.0005
- By:
- Publication type:
- Article
3
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) -- diagnostic and therapeutic challenge.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 23, doi. 10.5603/HCP.2021.0003
- By:
- Publication type:
- Article
4
Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q- and trisomy 8+.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 18, doi. 10.5603/HCP.2021.0004
- By:
- Publication type:
- Article
5
Effectiveness and safety of ixazomib-lenalidomide--dexamethasone in high-cytogenetic-risk relapsed//refractory multiple myeloma -- results of the Polish Myeloma Group observational study.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 8, doi. 10.5603/HCP.2021.0002
- By:
- Publication type:
- Article
6
Tranexamic acid for traumatic brain injury? The old drug raises new debate.
- Published in:
- Hematology in Clinical Practice, 2021, v. 31, n. 1, p. 1, doi. 10.5603/HCP.2021.0007
- By:
- Publication type:
- Article